Treatment of multiple sclerosis: current concepts and future perspectives

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients

(2010) Richard A. Rudick et al.   ANNALS OF NEUROLOGY

Anti-JC virus antibodies: Implications for PML Risk Stratification

(2010) Leonid Gorelik et al.   ANNALS OF NEUROLOGY

Changes in B- and T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple Sclerosis

(2010) Laura Piccio et al.   ARCHIVES OF NEUROLOGY

Birth outcomes in women who have taken leflunomide during pregnancy

(2010) Christina D. Chambers et al.   ARTHRITIS AND RHEUMATISM

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity

(2010) Joanne L. Jones et al.   BRAIN

PEGylated Interferon Beta-1a: Meeting an Unmet Medical Need in the Treatment of Relapsing Multiple Sclerosis

(2010) Darren P. Baker et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

(2010) Chris H Polman et al.   LANCET NEUROLOGY

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

(2010) Daniel Wynn et al.   LANCET NEUROLOGY

Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study

(2010) Samantha Jilek et al.   LANCET NEUROLOGY

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study

(2010) G. Comi et al.   Multiple Sclerosis Journal

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

(2010) C. Ford et al.   Multiple Sclerosis Journal

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

(2010) Volker Brinkmann et al.   NATURE REVIEWS DRUG DISCOVERY

CRITICAL VASOSPASM DURING FINGOLIMOD (FTY720) TREATMENT IN A PATIENT WITH MULTIPLE SCLEROSIS

(2010) A. Schwarz et al.   NEUROLOGY

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

(2010) J. J. Marriott et al.   NEUROLOGY

Cross-sectional study assessing long-term safety of interferon- -1b for relapsing-remitting MS

(2010) A. T. Reder et al.   NEUROLOGY

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

(2010) Gavin Giovannoni et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies

(2009) Eugene O. Major   Annual Review of Medicine

Effect of Anti-CD25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple Sclerosis

(2009) Bibiana Bielekova et al.   ARCHIVES OF NEUROLOGY

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

(2009) K. R. Carson et al.   BLOOD

Neutralizing Antibodies to Interferon-β and other Immunological Treatments for Multiple Sclerosis

(2009) Florian Deisenhammer   CNS DRUGS

Fumaric Acid and its Esters: An Emerging Treatment for Multiple Sclerosis

(2009) D. Moharregh-Khiabani et al.   Current Neuropharmacology

Benefit-Risk Assessment of Leflunomide

(2009) Nicola Alcorn et al.   DRUG SAFETY

Pharmacological Treatment of Early Multiple Sclerosis

(2009) Olaf Stüve et al.   DRUGS

Identification of new sensitive biomarkers for thein vivoresponse to interferon-β treatment in multiple sclerosis using DNA-array evaluation

(2009) F. Sellebjerg et al.   EUROPEAN JOURNAL OF NEUROLOGY

Melanoma following treatment with alemtuzumab for multiple sclerosis

(2009) A. A. Pace et al.   EUROPEAN JOURNAL OF NEUROLOGY

B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis

(2009) Sara A. J. Thompson et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

(2009) G Comi et al.   LANCET

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY

Daclizumab in treatment of multiple sclerosis patients

(2009) EN Ali et al.   Multiple Sclerosis Journal

Absence of MxA induction by interferon   in patients with MS reflects complete loss of bioactivity

(2009) D. Hesse et al.   NEUROLOGY

Effect of neutralizing antibodies on biomarker responses to interferon beta: The INSIGHT study

(2009) A. R. Pachner et al.   NEUROLOGY

HEMORRHAGING FOCAL ENCEPHALITIS UNDER FINGOLIMOD (FTY720) TREATMENT: A CASE REPORT

(2009) F. Leypoldt et al.   NEUROLOGY

Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab

(2009) Yiping Chen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term daclizumab therapy in relapsing-remitting multiple sclerosis

(2009) Monica A. Rojas et al.   Therapeutic Advances in Neurological Disorders

HLA-DRB1∗0401 and HLA-DRB1∗0408 Are Strongly Associated with the Development of Antibodies against Interferon-β Therapy in Multiple Sclerosis

(2008) Steve Hoffmann et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

(2008) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis

(2008) C. L. Hirst et al.   JOURNAL OF NEUROLOGY

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) G Comi et al.   LANCET

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) Ludwig Kappos et al.   LANCET

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY

Temporal trends in the incidence of multiple sclerosis: A systematic review

(2008) A. Alonso et al.   NEUROLOGY

Anti–Glomerular Basement Membrane Disease after Alemtuzumab

(2008) Menna R. Clatworthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE